Supplemental digital content: 1. Genes covered in the TUM01 NGS tumor panel: list of all genes covered by the panel. 2. Primer and Probes for TaqMan-Assays: sequence of primers used for TaqMan-Assays. 3. Digitial droplet PCR: detailed description of PCR as performed for this study, illustrated by Additional file 2: Figure S1 and Additional file 3: Figure S2. 4. Specific Mutation Pattern of Tumors: list of all detected mutations in the tumors of this study population with detailed explanation on position, kind of mutation, amino acid change and nucleotide change. 5. BioAnalyzer – cfDNA: description of fragment size distribution, illustrated by Additional file 4: Figure S3. (DOCX 60 kb
Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina), which includes 21...
List of Histone H3 Primer Sequences. The sequences and properties of primers used in this study are ...
Table S1. Data description of TCGA RNA sequencing data. Table S2. List of antibody-drug conjugates. ...
Figure S2. ddPCR Assays optimization (tumor). DNA from the respective tumor tissue was used as input...
Figure S3. Fragment Size Distribution. Typical image of a fragment size distribution analysis of cir...
Figure S1. ddPCR Assays optimization (blood). DNA from the respective blood sample was used as input...
Figure S1. Schematic overview of the computational pipeline to identify somatic mutations in NG-TAS ...
Table S1. Clinical characteristics of the patientsâ cohort. Samples from 42 patients were availabl...
Clinical and treatment characteristics of the 18 cases with no ctDNA alterations detected. Table S2....
Table S2. List of genes and genomic coordinates of the corresponding hotspots covered by Oncomineâ˘...
Figure S1. Result of EGFR E746_A750del in CSF cells of Patient #12 by ddPCR system. Y-axis means the...
Figure S1. Correlation between amount of total cfDNA yields (pg/mL) and EGFR-activating mutated alle...
Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...
Materials and methods. Table S1. Patient demographics and clinical characteristics. Table S2. Concen...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina), which includes 21...
List of Histone H3 Primer Sequences. The sequences and properties of primers used in this study are ...
Table S1. Data description of TCGA RNA sequencing data. Table S2. List of antibody-drug conjugates. ...
Figure S2. ddPCR Assays optimization (tumor). DNA from the respective tumor tissue was used as input...
Figure S3. Fragment Size Distribution. Typical image of a fragment size distribution analysis of cir...
Figure S1. ddPCR Assays optimization (blood). DNA from the respective blood sample was used as input...
Figure S1. Schematic overview of the computational pipeline to identify somatic mutations in NG-TAS ...
Table S1. Clinical characteristics of the patientsâ cohort. Samples from 42 patients were availabl...
Clinical and treatment characteristics of the 18 cases with no ctDNA alterations detected. Table S2....
Table S2. List of genes and genomic coordinates of the corresponding hotspots covered by Oncomineâ˘...
Figure S1. Result of EGFR E746_A750del in CSF cells of Patient #12 by ddPCR system. Y-axis means the...
Figure S1. Correlation between amount of total cfDNA yields (pg/mL) and EGFR-activating mutated alle...
Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...
Materials and methods. Table S1. Patient demographics and clinical characteristics. Table S2. Concen...
Table S1. Clinical and pathological characteristics for eligible patients in the I-SPY cohort. Table...
Table S1. 48 genes included in the TruSeq Amplicon Cancer Panel (TSACP, Illumina), which includes 21...
List of Histone H3 Primer Sequences. The sequences and properties of primers used in this study are ...
Table S1. Data description of TCGA RNA sequencing data. Table S2. List of antibody-drug conjugates. ...